Table: Nxera Pharma -2025 parent results
Feb 13 (Reuters)-
Nxera Pharma Co., Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Dec 31, 2025 Dec 31, 2024 Dec 31, 2026 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 19.05 6.58
(+189.4 pct) (+31.2 pct)
Operating 2.61 loss 4.62
Recurring 713 mln loss 1.55
Net loss 23.69 2.14
EPS loss 262.41 yen 23.89 yen
EPS Diluted 19.63 yen
Ann Div NIL NIL NIL
-Q2 Div NIL NIL NIL
-Q4 Div NIL NIL NIL
NOTE - Nxera Pharma Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up